People: StemCells Inc (STEM.O)
1.93USD
17 May 2013
$0.06 (+3.21%)
$1.87
$1.88
$1.93
$1.87
517,740
325,585
$2.67
$0.59
McGlynn, Martin
Brief Biography
Mr. Martin M. McGlynn serves as President, Chief Executive Officer, Director of StemCells Inc. Mr. McGlynn joined the company in January 2001, when he was appointed President and Chief Executive Officer of the company and of its wholly-owned subsidiaries. Mr. McGlynn was elected to the Board of Directors in February 2001.
Basic Compensation
| Total Annual Compensation, USD | Long-Term Incentive Plans, USD | All Other, USD | Fiscal Year Total, USD |
|---|---|---|---|
| 712,688 | -- | 48,819 | 955,507 |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | 844,791 | 1,121,590.00 |
| Unexercisable | 330,209 | 683,635.00 |
| Excercised | 146,000 | 376,680.00 |
| Name | Fiscal Year Total |
|---|---|
John Schwartz |
-- |
Martin McGlynn |
955,507 |
Rodney Young |
436,342 |
Ann Tsukamoto |
402,444 |
Stewart Craig |
374,388 |
Kenneth Stratton |
375,945 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
